Mohammad Pakravan

Mohammad Pakravan

Auto-generated profile, based on publicly available information

Mohammad Pakravan

Blanton Eye Institute, Houston Methodist Hospital, Houston, TX

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Ophthalmology
Verified
Journal Article
Closed access
MPMohammad Pakravan
Mohammad Pakravan
SYShahin Yazdani
Shahin Yazdani
MJMohammad-Ali Javadi
Mohammad-Ali Javadi
HAHeidar Amini
Heidar Amini
ZBZohreh Behroozi
Zohreh Behroozi
MYMehdi Yaseri
Mehdi Yaseri

19 March 2012 in European Journal of Ophthalmology
Verified
Journal Article
Closed access
MPMohammad Pakravan
Mohammad Pakravan
MRMaryam Roshani
Maryam Roshani
SYShahin Yazdani
Shahin Yazdani
AFAmir Faramazi
Amir Faramazi
MYMehdi Yaseri
Mehdi Yaseri
Purpose: To evaluate the efficacy of pregabalin and gabapentin for reducing post–photorefractive keratectomy (PRK) pain. Methods: In this randomized clinical trial, 150 subjects undergoing PRK were allocated into 3 groups. In addition to the routine regimen, pregabalin 75 mg, gabapentin 300 mg, and placebo were administered 3 times daily for 3 days, in groups 1, 2, and 3, respectively. Subjects could take acetaminophen-codeine 300/10 mg tablets every 4 hours as needed. Patients completed a pain assessment survey (visual analogue scale ranging from 0 = no pain to 10 = most severe pain) 7 times in the first 3 days following PRK and also recorded the number of consumed acetaminophen-codeine tablets. Results: Age, sex, refractive error, ablation depth, and mitomycin-C (MMC) application were similar in the 3 study groups (all p values>0.05). Overall pain scores in the placebo group were 0.9 and 1 unit higher than the pregabalin (p=0.029) and gabapentin (p=0.023) groups, respectively. Severe pain (score >7) was more frequent in the placebo group on the morning of the first postoperative day (p=0.043). The difference in the number of consumed acetaminophen-codeine tablets was statistically borderline (p=0.061) and less in the pregabalin (7.9±5.2) and gabapentin (9.0±4.1) groups in comparison to the placebo group (10.3±5.6). Conclusions: Pregabalin and gabapentin seem to be helpful in alleviating post-PRK pain when combined with other measures. Depending on availability, either compound can be used as an adjuvant for pain control in this setting.

1 December 2012 in Journal of Neuro-Ophthalmology
Verified
Journal Article
Closed access
MPMohammad Pakravan
Mohammad Pakravan
NSNasrin Sanjari
Nasrin Sanjari
To present the effect of erythropoietin for the treatment of methanol optic neuropathy. Two patients with methanol optic neuropathy were treated with 10,000 IU of intravenous erythropoietin twice a day for 3 days, 500 mg of methylprednisolone twice a day for 5 days (followed by 2 weeks of oral prednisolone [1 mg/kg per day]), and daily doses of vitamin B12, vitamin B6, and folic acid for 1 month. At presentation, the patients had no perception of light in both eyes, associated with mildly swollen optic discs. Both responded dramatically to the treatment regimen. In the first patient, visual acuity improved to 20/20 in both eyes within 3 days, whereas in the second patient, visual acuity returned to counting fingers at 6 feet, right eye, and 20/30, left eye, within 3 weeks. Intravenous erythropoietin may be an effective adjuvant when combined with current treatment for patients with methanol optic neuropathy.

1 January 2014
Verified
Journal Article
Open access
MPMohammad Pakravan
Mohammad Pakravan
MAMohsen Afroozifar
Mohsen Afroozifar
SYShahin Yazdani
Shahin Yazdani
To determine corneal biomechanical changes following major glaucoma procedures. In a prospective comparative case series, corneal biomechanical properties were assessed using the Ocular Response Analyzer (ORA, Reichert Inc., Depew, New York, USA) before and 3 months after surgery in 89 eyes of 89 patients undergoing trabeculectomy + mitomycin C (MMC) (23 eyes, group 1), phacotrabeculectomy + MMC (23 eyes; group 2), Ahmed glaucoma valve (AGV) implantation (17 eyes; group 3) or phacoemulsification (PE) alone (26 non-glaucomatous eyes; group 4). Patients with history of contact lens use, previous intraocular surgery, any chronic corneal disease, central corneal thickness ≥580 microns or ≤500 microns, post-operative intraocular pressure (IOP) > 21 mmHg or ≤ 5 mmHg, and any surgical complication were excluded. Main outcome measures included changes in corneal hysteresis (CH) and corneal resistance factor (CRF). Preoperatively, CH was lower in glaucomatous versus non-glaucomatous eyes (5.4, 5.3, 5.2 and 8.1 mmHg in groups 1, 2, 3 and 4 respectively, p<0.001). Three months after surgery, mean CH increased by 2.16, 2.29 and 2.30 mmHg in groups 1, 2 and 3 respectively (P<0.001) but only by 0.11 mmHg in group 4 (p=0.704). The postoperative increase in CH in glaucomatous eyes was more significant when IOP was reduced by more than 10 mmHg. CRF also showed a significant increase in all study groups postoperatively (P<0.001). CH and CRF increased significantly 3 months after glaucoma procedures. Alterations in corneal biomechanical properties should be considered when measuring IOP after successful glaucoma surgery.

1 January 2021 in Ophthalmology Glaucoma
Verified
Journal Article
Closed access
SYShahin Yazdani
Shahin Yazdani
ABAfsaneh Naderi beni
Afsaneh Naderi beni
MPMohammad Pakravan
Mohammad Pakravan

30 November 2023 in Journal of Ophthalmic and Vision Research
Verified
Journal Article
Open access
PDF file
SDSepideh Jamali Dogahe
Sepideh Jamali Dogahe
PPParastou Pakravan
Parastou Pakravan
MPMohammad Pakravan
Mohammad Pakravan
This review discusses the physical examination and diagnostic tests necessary to diagnose optic neuritis (ON) and provides an update on the approach and management of acute ON. A comprehensive search of the PubMed database was conducted, limited to English-language journals and recent publications. A total of 160 articles were initially screened by title, of which 73 articles were included in the narrative synthesis. ON is an inflammation of the optic nerve that can be caused by different systemic and neurological disorders. It is commonly presented as a subacute unilateral painful vision loss, and based on its clinical manifestation, it can be classified as typical or atypical. Atypical ON is bilateral with visual acuity of worse than 20/200 or has an atypical demographic presentation for demyelination, such as a non-Caucasian male with optic disc swelling, for which neuromyelitis optica spectrum disorder (NMOSD), myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD), or other etiologies should be considered. Steroids and immunosuppressants are the main treatment options for ON, and timely treatment initiation is critical to preventing irreversible vision loss, especially in atypical cases.